Article Details
Retrieved on: 2023-11-21 00:35:31
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Vigil Neuroscience expects additional results from its phase 2 IGNITE study using iluzanebart in Q324. Read why I rate VIGL stock a Strong Buy.
Article found on: seekingalpha.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here